Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of “Buy” by Analysts

Shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) have earned an average recommendation of “Buy” from the five brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a strong buy rating on the company.

A number of equities analysts recently weighed in on IKT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen raised shares of Inhibikase Therapeutics to a “sell” rating in a research note on Saturday, December 27th. HC Wainwright raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Friday, December 26th. Zacks Research upgraded shares of Inhibikase Therapeutics to a “hold” rating in a report on Tuesday, December 2nd. Finally, Lifesci Capital raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a research note on Monday, December 1st.

Inhibikase Therapeutics Trading Up 1.2%

IKT opened at $1.69 on Friday. The company has a market cap of $127.05 million, a price-to-earnings ratio of -4.33 and a beta of 0.84. The stock’s fifty day moving average is $1.70. Inhibikase Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $3.32.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.